在患有性结肠炎的患者中,坚持地中海-DASH干预神经退行性延迟饮食和疾病严重程度之间的关联
Zeinab Nikniaz1, Reza Mahdavi2, Zahra Bakhtiari3
1Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. znikniaz@hotmail.com.
Scientific reports
|July 2, 2025
概括
坚持地中海-DASH干预神经退行性延迟 (MIND) 饮食可能会减少性结肠炎 (UC) 的严重程度. 在这项研究中,较高的MIND饮食得分与较低的严重UC几率有关.
科学领域:
- 营养科学 营养科学
- 胃肠病学 胃肠病学
- 慢性疾病管理 慢性疾病管理
背景情况:
- 性结肠炎 (UC) 管理需要有效诱导和维持缓解.
- 饮食模式越来越多地被认为是它们在调节UC疾病严重性的作用.
- 地中海-DASH干预神经退行性延迟 (MIND) 饮食结合了地中海和DASH饮食的各个方面.
研究的目的:
- 研究坚持MIND饮食与UC患者疾病严重程度之间的关联.
- 为了确定更高的MIND饮食得分是否与UC严重性降低相关.
- 分析与UC严重程度相关的饮食摄入模式.
主要方法:
- 包括158名UC患者在内的横截面研究.
- 疾病严重程度由胃肠病学家使用梅奥得分来评估.
- 通过168项食物频率问卷评估饮食摄入量;计算MIND饮食得分.
- 对共变量调整后的物流回归分析.
主要成果:
- 拥有较高MIND饮食分数的患者消耗了更多的蔬菜,果,坚果和橄油,并减少了炸食品.
- 对MIND饮食的更高坚持与严重UC的几率明显降低相关 (OR:0.39,95%CI:0.16,0.97).
- 除了使用普得尼索隆和遵守特殊饮食外,MIND饮食分数第三种动物之间没有显著的人口差异.
结论:
- 对MIND饮食的高度坚持与严重性结肠炎的几率较低显著相关.
- MIND饮食可能是一种有益的饮食干预措施,用于管理UC的严重程度.
- 需要进一步的前性和干预性研究来证实这些发现.
更多相关视频
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
430
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
430
Inflammatory Bowel Disease I: Ulcerative Colitis
342
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
342
Drugs for Treatment of Ulcerative Colitis in IBD
243
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
243
Chronic Bowel Disorders: Introduction
542
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
542
Drugs for Treatment of Diarrhea-Predominant IBS
312
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
312
Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41


